Wall Street analysts forecast that Reata Pharmaceuticals Inc (NASDAQ:RETA) will report $11.18 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Reata Pharmaceuticals’ earnings, with the highest sales estimate coming in at $12.60 million and the lowest estimate coming in at $7.19 million. Reata Pharmaceuticals posted sales of $12.50 million during the same quarter last year, which would indicate a negative year over year growth rate of 10.6%. The business is scheduled to announce its next quarterly earnings results on Friday, March 2nd.

On average, analysts expect that Reata Pharmaceuticals will report full year sales of $11.18 million for the current fiscal year, with estimates ranging from $45.20 million to $50.70 million. For the next financial year, analysts expect that the business will post sales of $45.81 million per share, with estimates ranging from $28.20 million to $50.46 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The firm had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. The company’s quarterly revenue was up .0% compared to the same quarter last year.

Several equities research analysts have recently weighed in on RETA shares. Citigroup reiterated a “buy” rating and issued a $78.00 price target (down from $87.00) on shares of Reata Pharmaceuticals in a report on Wednesday, August 23rd. Jefferies Group started coverage on Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 price target on the stock. Robert W. Baird reiterated a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a report on Friday, September 1st. ValuEngine downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 11th. Finally, Leerink Swann started coverage on Reata Pharmaceuticals in a research note on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 price objective on the stock. Three research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. Reata Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $54.71.

Shares of Reata Pharmaceuticals (NASDAQ:RETA) opened at $25.40 on Monday. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18. Reata Pharmaceuticals has a fifty-two week low of $18.51 and a fifty-two week high of $40.88.

In other news, Director James Edward Bass acquired 3,888 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average price of $24.02 per share, with a total value of $93,389.76. Following the completion of the purchase, the director now directly owns 52,089 shares in the company, valued at $1,251,177.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 44.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in RETA. Nationwide Fund Advisors boosted its position in Reata Pharmaceuticals by 38.1% during the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock valued at $138,000 after acquiring an additional 1,206 shares in the last quarter. Wells Fargo & Company MN boosted its position in Reata Pharmaceuticals by 37.4% during the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock valued at $176,000 after acquiring an additional 1,521 shares in the last quarter. First Allied Advisory Services Inc. bought a new stake in Reata Pharmaceuticals during the 3rd quarter valued at $203,000. The Manufacturers Life Insurance Company boosted its position in Reata Pharmaceuticals by 102.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock valued at $233,000 after acquiring an additional 3,715 shares in the last quarter. Finally, American International Group Inc. boosted its position in Reata Pharmaceuticals by 42.5% during the 3rd quarter. American International Group Inc. now owns 7,528 shares of the company’s stock valued at $234,000 after acquiring an additional 2,247 shares in the last quarter. 29.61% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc (RETA) Will Announce Quarterly Sales of $11.18 Million” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/11/zacks-brokerages-anticipate-reata-pharmaceuticals-inc-reta-will-announce-quarterly-sales-of-11-18-million.html.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.